Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections

Current Ophthalmology Reports

Volumn 2, Issue 1, 2014, Pages 1-5

  Schwartz, Stephen G ^a   Flynn, Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Endophthalmitis; Intravitreal injection; Ophthalmology; Ranibizumab; Vascular endothelial growth factor (VEGF)

Indexed keywords

EID: 84906812302     PISSN: None     EISSN: 21674868     Source Type: Journal    
DOI: 10.1007/s40135-013-0033-1     Document Type: Article

References (50)

1. Ramulu PY, Do DV, Corcoran KJ, Corcoran SL, Robin AL. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128(10):1335–40.
2. Schwartz SG, Flynn HW Jr, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother. 2009;10(13):2119–26.
3. Schwartz SG, Flynn HW Jr, Scott IU. Endophthalmitis: classification and current management. Expert Rev Ophthalmol. 2007;2(3):385–96.
4. Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. 2012;96(6):862–6.
5. Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(12):2630–6.
6. Gillies MC, Walton R, Simpson JM, et al. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes. Invest Ophthalmol Vis Sci. 2013;54(8):5754–60.
7. Englander M, Chen TC, Paschalis EI, Miller JW, Kim IK. Intravitreal injections at the Massachusetts eye and ear infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol. 2013;97(4):460–5.
8. • Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular (corrected) endothelial growth factor antagonists: a 6-year experience at a university referral center. Retina. 2011;31(4):662–8. A case series of endophthalmitis following intravitreal anti-VEGF injections in a very large (60,322) series.
9. Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26(12):1517–26.
10. Fineman HS, Hsu J, Sprin MJ, Kaiser RS. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33(9):1968–70.
11. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266–72.
12. Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology. 2012;119(7):1388–98.
13. IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: 1-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411.
14. • Sheyman AT, Cohen BZ, Friedman AH, Ackert JM. An outbreak of fungal endophthamitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol. 2013;131(7):864–9. A report of an outbreak of endophthalmitis associated with contaminated bevacizumab plus triamcinolone from a compounding pharmacy
15. • Goldberg RA, Flynn HW Jr, Miller D, Gonzalez S, Isom RF. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: 1-year outcomes and investigative results. Ophthalmology. 2013;120(7):1448–53. A report of a severe outbreak of endophthalmitis associated with contaminated bevacizumab from a compounding pharmacy.
16. Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina. 2010;30(3):485–90.
17. Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2013 (in press).
18. Entezari M, Ramezani A, Ahmadieh H, Ghasemi H. Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab. Indian J Ophthalmol. 2013 (in press).
19. Sharma S, Johnson D, Abouammoh H, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275–9.
20. Cunningham MA, Tlucek P, Folk JC, Boldt HC, Russell SR. Sequential, acute noninfectious uveitis associated with separate intravitreal injections of bevacizumab and ranibizumab. Retin Cases Brief Rep. (in press).
21. Wang F, Yu S, Liu K, et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology. 2013;120(2):355–61.
22. Schachat AP, Rosenfeld PJ, Liesegang TJ, Stewart MW. Endophthalmitis is not a “never event”. Ophthalmology. 2012;119(8):1507–8.
23. McCannell CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–61.
24. Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intravitreal injection: the importance of Viridans streptococci. Retina. 2011;31(8):1525–33.
25. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551–4.
26. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina. 2012;32(3):473–6.
27. Shimada H, Hattori T, Mori R. Minimizing the endophthalmitis rate following intravitreal injections using 0.25 % povidone-iodine irrigation and surgical mask. Gaefes Arch Clin Exp Ophthlamol. 2013;251(8):1885–90.
28. Romero-Aroca P, Sararols L, Arias L, Casaroli-Marano RP, Bassaganyas F. Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection. Clin Ophthalmol. 2012;6:1595–9.
29. Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33(5):971–4.
30. Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–14.
31. Bhavsar AR, Stockdale CR, Ferris FL, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthlamol. 2012;130(6):809–10.
32. Yin VT, Wesibrod DJ, Eng KT, et al. Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol. 2013;131(4):456–61.
33. Alabiad CR, Miller D, Schiffman JC, Davis JL. Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections. Am J Ophthalmol. 2011;152(6):999–1004.
34. Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96(12):1474–8.
35. Tabandeh H, Boscia F, Sborgia A et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2013 (in press).
36. Ikuno Y, Sawa M, Tsujikawa M, et al. Effectiveness of 1.25 % povidone-iodine combined with topical levofloxacin against conjunctival flora in intravitreal injection. Jpn J Ophthalmol. 2012;56(5):497–501.
37. Lad EM, Maltenfort MG, Leng T. Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection. Ophthalmic Surg Lasers Imaging. 2012;43(2):115–20.
38. Chen SD, Mohammed Q, Bowling B, Patel CK. Vitreous wick syndrome: a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am J Ophthalmol. 2004;137(6):1159–60.
39. Christoforidis JB, Williams MM, Epitropoulos FM, Knopp MV. Subconjunctival bleb that forms at the injection site after intravitreal injection is drug, not vitreous. Clin Exp Ophthalmol. 2013;41(6):614–5.
40. Woo SJ, Han JM, Ahn J, et al. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina. 2012;32(4):667–71.
41. Tabatabaii A, Ahmadraji A, Khodabande A, Mansouri M. Acute bilateral endophthalmitis following bilateral intravitreal bevacizumab (Avastin) injection. Middle East Afr J Ophthlamol. 2013;20(1):87–8.
42. Kugu S, Sevim MS, Kaymak NZ, et al. Exogenous group G Streptococcus endophthalmitis following intravitreal ranibizumab injection. Clin Ophthlamol. 2012;6:1399–402.
43. Joshi L, Morarji J, Tomkins-Netzer O, Lightman S, Taylor SR. Rhizobium radiobacter endophthalmitis following intravitreal ranibizumab injection. Case Rep Ophthalmol. 2012;3(3):283–5.
44. Pinarci EY, Yesilirmak N, Bayar SA, et al. The results of pars plana vitrectomy and silicone oil tamponade for endophthalmitis after intravitreal injections. Int Ophthalmol. 2013;33(4):361–5.
45. Chaudhary KM, Romero JM, Ezon I, Fastenberg DM, Deramo VA. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection. Retina. 2013;33(7):1407–16.
46. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn’t blind people, people blind people. Am J Ophthalmol. 2012;153(2):196–203.
47. Shienbaum G, Flynn HW Jr. Compounding bevacizumab for intravitreal injection: does USP 〈797〉 always apply? Retina. 2013;33(9):1733–4.
48. Schimel AM, Scott IU, Flynn HW Jr. Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol. 2011;129(12):1607–9.
49. Wykoff CC, Flynn HW Jr, Rosenfeld PJ. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol. 2011;152(5):717–9.
50. Chen RW, Rachitskaya A, Scott IU, Flynn HW. Is the use of topical antibiotics for intravitreal injections the standard of care or are we better off without antibiotics? JAMA Ophthalmol. 2013;131(7):840–2.